MK

Manjunath Kumaraswamy

Active Director Director DIN 08500781
DIN 08500781 First appointment Jul 2019 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2019
Shareholding value •••• Premium profile

About Manjunath Kumaraswamy

Data last updated:

Manjunath Kumaraswamy is a Director at Nectaro Pharma Private Limited (since 2019). The company operates in Chemicals. Nectaro Pharma Private Limited reported revenue of ₹4.62 Cr (FY 2025).

DIN 08500781
Primary Designation Director
Industry Chemicals
First Appointment 04 Jul 2019
Oldest Company Age 7 yrs
Largest company Nectaro Pharma Private Limited · ₹4.62 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Nectaro Pharma Private Limited U24290KA2019PTC125887
Director04 Jul 20192019₹4.62 Cr (FY 2025)Active

Board colleagues of Manjunath Kumaraswamy

Directorship timeline

Open interactive timeline →
Nectaro Pharma Private Limited
Premium access

Shareholding and investment profile for Manjunath Kumaraswamy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manjunath Kumaraswamy

Manjunath Kumaraswamy currently holds 1 directorship: Nectaro Pharma Private Limited (Director, since 04 Jul 2019, revenue ₹4.62 Cr (FY 2025)).

Manjunath Kumaraswamy was first appointed on 04 Jul 2019 as Director at Nectaro Pharma Private Limited.

The current boards of Manjunath Kumaraswamy's companies include Neralakere Siddappa Siddarameswar (Nectaro Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available